Merck Sharp + Dohme Corp.

Nanosystems L.l.c.

Eastman-kodak Company

Elan Pharma International Limited

Nanosystem L.l.c.

Nawosystems L.l.c.

W Mark Eickhoff

Stephen B Ruddy

Craig B Ikeda

Chad D Brown

Hanmi Xi

Lisa Lupton

Rebecca Nofsinger

Francis J Flanagan, Jr

Gary G Liversidge

Paresh B Patel

Wei Xu

Leonardo Resende Allain

Mary Ann Johnson

Melanie Marota

David A Engers

Karl R Mueller

Eugene Rex Cooper

Pramod P Sarpotdar

Kathleen J Illig

Mary E Roberts

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.

Treatment of migraine

Pharmaceutical formulations for the treatment of migraine

The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): wherein 'R' is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.

Tablet formulation for CGRP active compounds

The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein 'R' is independently H or &#x2014;F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released. 

Particulate crystalline therapeutic substances are formulated with stabilizers to enhance contact between the crystalline therapeutic substances and the mucosal membranes to provide extended therapeutic effect.

Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract

Nanoparticulate crystalline x-ray contrast agents are formulated with stabilizers to enhance contact between the crystalline x-ray contrast agents and the gastrointestinal tract. Nanoparticulate crystalline therapeutic substances also formulated with stabilizers to enhance contact between the crystalline therapeutic substances and the gastrointestinal tract and to provide extended therapeutic effect.

Formulations of oral gastrointestinal diagnostic x-ray contrast agents

Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising nanoparticles of a barium salt having associated with its surface non-ionic and anionic stabilizers; and methods for their use in diagnostic radiology of the gastrointestinal tract.

Barium salt formulations stabilized by non-ionic and anionic stabilizers

Nanoparticulate crystalline therapeutic substances formulated with stabilizers and pharmaceutically acceptable clays to enhance contact between the crystalline therapeutic substances and the gastrointestinal tract and to provide extended therapeutic effect.

Formulations of oral gastrointestinal therapeutic agents in combination

Nanoparticulate crystalline therapeutic or diagnostic substances formulated with stabilizers and high molecular weight, linear poly(ethylene oxide) polymers, enhance contact between the crystalline therapeutic or diagnostic substances and the gastrointestinal tract providing site-specific and extended therapeutic or diagnostic effect.

Site-specific adhesion within the GI tract using nanoparticles

Nanoparticulate crystalline drug substances formulated in an aqueos phase emulsified in oil, are able to be made at less than 1000 nm size and provide increased bioavailability and lymphatic uptake following oral administration.

Formulations of compounds as nanoparticulate dispersions in digestible

A composition comprising a crystalline NSAID having polyvinylpyrrolidone adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 1000 nm, hygroscopic sugar and sodium lauryl sulfate exhibit greatly reduced gastric irritation following oral administration and/or hastened onset of action due to the substantial redispersion of the solid formulation to nanoparticles in gastric fluid.

Growing community of inventors

Downingtown, PA, United States of America

W Mark Eickhoff